Impella Pump Return Study to Analyze Deposits and Biomaterial in Used Pumps
- Conditions
- Heart Failure
- Registration Number
- NCT06765226
- Lead Sponsor
- Abiomed Inc.
- Brief Summary
Analysis of cell and protein deposits on the Impella Heart Pump.
- Detailed Description
The Impella heart pump supports patients in cardiogenic shock for various reasons and has passed safety and biocompatibility evaluations. The planned investigation aims to further analyze cell and protein adhesion on these pumps and the effects of their prolonged use, especially in scenarios like bridge-to-transplant, recognizing preclinical testing limitations.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 200
- Patients with Impella 5.5 therapy and duration of support for ≥ 25 days OR Patients with Impella CP therapy and duration of support for > 4 days
- Use of Sodium Bicarbonate as a purge additive as permitted by the IFU
- Age < 18 years
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Investigate deposits and biomaterial after use of pump through study completion, at least 25 days investigate Impella 5.5 pumps after use regarding deposits and biomaterial
- Secondary Outcome Measures
Name Time Method Relation deposits and biomaterial to clinical events through study completion, at least 25 days By correlating patient data, such as medical history and Impella 5.5 related blood parameters, with the findings from our pump analysis, potential connections between medication, diseases, comorbidities, and deposits on the pump can be identified.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (2)
Herzzentrum Dresden
🇩🇪Dresden, Saxony, Germany
Deutsches Herzzentrum der Charité Berlin
🇩🇪Berlin, Germany